Ardena appoints Jeremie Trochu as Chief Executive Officer

Leadership Transition - Harry Christiaens, PhD, retires as CEO after 20 years of leadership, remaining on the Board [1] - Jeremie Trochu appointed as new CEO, bringing 20 years of experience in the biopharma and CDMO industry [1][2] - Jeremie Trochu has a proven track record in global business growth, market expansion, and large-scale transformations, with deep transatlantic experience in European and North American markets [2] Company Growth and Vision - Ardena has grown from a local 10-person consultancy to a world-leading CDMO with over 500 employees and five facilities across Europe under Harry Christiaens' leadership [3] - The company recently invested EUR 25 million in state-of-the-art GMP nanomedicine and aseptic fill-finish capabilities [3] - Jeremie Trochu's global mindset and US market experience align with Ardena's ambitions for international expansion [3] Industry Expertise and Services - Ardena is a leading CDMO specializing in advanced drug development for innovative and complex molecules, aiming to accelerate therapies to the clinic and patients [4] - The company provides integrated services including solid-state chemistry, API and nanomedicine development, analytical and formulation development, drug product manufacturing, and regulatory services [5] - Ardena serves a wide range of clients, from emerging biotechs to big pharma, supporting drug discovery and development processes [5]